Anebulo Pharmaceuticals’ (ANEB) “Speculative Buy” Rating Reiterated at Benchmark

Anebulo Pharmaceuticals (NASDAQ:ANEB)‘s stock had its “speculative buy” rating restated by research analysts at Benchmark in a research report issued on Tuesday,Benzinga reports. They currently have a $8.00 target price on the stock. Benchmark’s price objective suggests a potential upside of 422.88% from the stock’s current price.

Anebulo Pharmaceuticals Trading Down 3.7 %

Shares of NASDAQ ANEB opened at $1.53 on Tuesday. Anebulo Pharmaceuticals has a 12-month low of $1.46 and a 12-month high of $3.30. The company has a market cap of $39.67 million, a P/E ratio of -5.10 and a beta of -1.00. The stock has a fifty day moving average price of $1.90 and a 200 day moving average price of $2.11.

Anebulo Pharmaceuticals (NASDAQ:ANEB) last announced its quarterly earnings results on Wednesday, September 25th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.08. On average, sell-side analysts forecast that Anebulo Pharmaceuticals will post -0.52 EPS for the current fiscal year.

About Anebulo Pharmaceuticals

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.